Clinical trial for Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Official title Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ClinicalTrials.gov ID: NCT06806033
What this study is testing
What is Obinutuzumab?
An investigational intravenous medicine being studied for relapsed or refractory aggressive B‑cell Non‑Hodgkin’s lymphoma. is designed to target CD20 on B‑cells.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether using a special steroid plan and careful monitoring can make glofitamab safer and easier to give at home. It also looks at whether adding gemcitabine and oxaliplatin helps.
- Who it's for
- You may be able to join if you have aggressive B‑cell lymphoma that has come back or did not respond to earlier treatments.
- What's involved
- You would receive the drug glofitamab, sometimes with two other medicines, and you would have regular check‑ups and blood tests. The doctors will give you steroids before the treatment to reduce side effects.
- Time commitment
- The study lasts several months, with visits at the start, during treatment, and later check‑ins to monitor your health.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Life expectancy \>= 12 weeks.
- For participants in the Glofit-GemOx combination therapy cohort (Cohort A) and the glofitamab monotherapy cohort (Cohort B), participant with...
- Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified (NOS).
- High-Grade B-Cell Lymphoma (HGBL), NOS.
- DLBCL/HGBL with myelocytomatosis proto-oncogene (MYC) and B-cell lymphoma 2 (BCL2) rearrangements.
You likely can't join if
- Prior enrollment in Studies GO41943 (NCT04313608), GO41944 (STARGLO; NCT04408638), or Study GO44900 (NCT06624085).
- Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation.
- Any history of Waldenstrom's macroglobulinemia.
- Primary mediastinal B-cell lymphoma.
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins)...
- Contraindication to obinutuzumab, gemcitabine or oxaliplatin, or tocilizumab.
See the full eligibility criteria
Who can join
- Life expectancy \>= 12 weeks.
- For participants in the Glofit-GemOx combination therapy cohort (Cohort A) and the glofitamab monotherapy cohort (Cohort B), participant with histologically confirmed diffuse large B-cell lymphoma, (de novo or...
- Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified (NOS).
- High-Grade B-Cell Lymphoma (HGBL), NOS.
- DLBCL/HGBL with myelocytomatosis proto-oncogene (MYC) and B-cell lymphoma 2 (BCL2) rearrangements.
- R/R disease, defined as: relapsed = disease that has recurred following a response that lasted \>/= 6 months after completion of the last line of therapy
- At least one line of prior systemic therapy.
- Participants who have failed one prior line of therapy (eligible to Cohort A) must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant.
- At least one bi-dimensionally measurable (\> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (\> 1 cm) extranodal lesion, as measured on CT scan.
- Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2.
- According to the investigator's judgment, participants should be able to receive the step-up dose regimen in an outpatient setting.
What rules you out
- Prior enrollment in Studies GO41943 (NCT04313608), GO41944 (STARGLO; NCT04408638), or Study GO44900 (NCT06624085).
- Participant has failed only one prior line of therapy and is a candidate for stem cell transplantation.
- Any history of Waldenstrom's macroglobulinemia.
- Primary mediastinal B-cell lymphoma.
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products.
- Contraindication to obinutuzumab, gemcitabine or oxaliplatin, or tocilizumab. For participants in the monotherapy cohort (Cohort B), participants with contraindication to obinutuzumab or tocilizumab will be excluded.
- Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3.
- For the Glofit-GemOx combination therapy cohort (Cohort A), prior treatment with gemcitabine or oxaliplatin.
- For the Glofit-GemOx combination therapy cohort (Cohort A), peripheral neuropathy or paresthesia assessed to be Grade \>= 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI...
- Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment.
- Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment.
- Primary or secondary CNS lymphoma at the time of recruitment.
- Prior CNS involvement that has been definitively treated and confirmed via magnetic resonance imaging (MRI) or cerebrospinal fluid analysis to be in complete remission is permissible.
- Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
- History of other primary malignancy, with exceptions defined by the protocol.
- Significant or extensive cardiovascular disease.
- Significant pulmonary disease (including moderate or severe obstructive pulmonary disease).
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator)...
- Positive for: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); chronic active Epstein-Barr viral infection.
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) or progressive multifocal leukoencephalopathy.
- Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia).
- Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study.
- Prior solid organ transplantation or prior allogenic stem cell transplant.
- Active autoimmune disease requiring treatment.
- Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents), within 4 weeks prior to first...
- Ongoing systemic corticosteroid use which, in the opinion of the investigator, puts the participant at increased risk of steroid-related iatrogenic adrenal insufficiency.
- Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis.
- Clinically significant history of cirrhotic liver disease.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or...
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after the final dose of study treatment.
The study team makes the final eligibility decision.
Where it is enrolling
- Anchorage, Alaska, United States
- Clovis, California, United States
- Fullerton, California, United States
- Los Angeles, California, United States
- Panorama City, California, United States
- San Francisco, California, United States
- Torrance, California, United States
- Aurora, Colorado, United States
- Miami, Florida, United States
- Orlando, Florida, United States
- Boise, Idaho, United States
- Swansea, Illinois, United States
- Waukee, Iowa, United States
- Lexington, Kentucky, United States
- Baton Rouge, Louisiana, United States
- Boston, Massachusetts, United States
- Grand Rapids, Michigan, United States
- Omaha, Nebraska, United States
- Albany, New York, United States
- East Syracuse, New York, United States
+ 24 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Anchorage, Alaska, United States; Clovis, California, United States; Fullerton, California, United States; Los Angeles, California, United States; Panorama City, California, United States; San Francisco, California, United States and 38 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.